UnitedHealth Group's CEO responds to Q1 earnings miss driven by Medicare Advantage medical cost surges and DOJ scrutiny, outlining reforms to manage rising care expenses and rebuild investor confidence.

Elevance Health outperforms competitors by managing Medicare Advantage costs effectively and driving robust growth in its Carelon segment, bolstering its 2025 outlook and earning a Strong Buy rating with growth potential.